$NAGE News

Niagen Bioscience Files Prospectus To Offer And Sell Common Stock Up To $50M

Niagen Bioscience Launches NAD Pharmaceuticals, Its Wholly Owned Subsidiary Focused On Developing Therapies For Accelerated Aging And Rare Genetic Diseases

Niagen Bioscience Inc. (NAGE) Renames Research Program Amid Focus in Advancing NAD+ Applications

Niagen Bioscience (NAGE) Stock Sees Split Analyst Revisions As Price Targets Fall

Assessing Niagen Bioscience (NAGE) Valuation As It Renames Its NAD+ Research Program

Niagen Bioscience to Present at the 16th Annual East Coast IDEAS Investor Conference

How The Niagen Bioscience (NAGE) Investment Story Is Evolving Without New Analyst Signals

Niagen Bioscience Renames ChromaDex External Research Program to the Niagen Research Program, Strengthening Position as the Global Leader in NAD+ Science

How The Niagen Bioscience (NAGE) Story Is Shifting As Price Targets Edge Lower

HC Wainwright & Co. Maintains Buy on Niagen Bioscience, Lowers Price Target to $11

Assessing Niagen Bioscience (NAGE) Valuation After Earnings Strength And New NAD Plus Delivery Initiatives

Will Niagen Bioscience’s (NAGE) Telehealth NAD+ Push Redefine Its Core Therapeutic Focus?

Niagen Bioscience Announces Participation in Upcoming Investor Conferences

Niagen Bioscience Keeps Full-Year Sales Forecast Intact As Q1 Revenue, Profit Climbs (UPDATED)

Niagen Bioscience (NASDAQ:NAGE) Shares Slide After Q1 Earnings Miss and Spending Guidance

Niagen Bioscience, Inc. (NAGE) Q1 2026 Earnings Call Transcript

Niagen Expects 2026 Net Sales To Increase Between 10-15% YoY, Excluding 2025 Net Sales Attributable To The Analytical Reference Standards And Services Segment

Niagen Bioscience Rolls Out Its Clinician-Directed Telehealth Platform Under Niagen Plus In U.S.

Insider Decision Unfolding At Niagen Bioscience: CEO Robert Fried Exercises Options(CORRECTED)

Insider Decision Unfolding At Niagen Bioscience: Robert Fried Exercises Options, Resulting In $46K